Drugs / ME-143
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01401868 | Sep 2011 → Sep 2012 | cancer | MEI Pharma, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ME-143 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01401868 ↗ |
| Route | Intravenous | “3 weekly IV infusions” NCT01401868 ↗ |